31st May 2022 | Pharma Updates

Bayer's consumer health division intends to expand its presence in India

Basel-based pharmaceutical company intends to bring more over-the-counter products from its global portfolio tailored to Indian consumer needs, as well as launch more line extensions of its top brands such as Saridon and Supradyn.

Sun Pharma reports Rs 2,277cr loss in the March quarter

Sun Pharma reported a surprise loss of Rs 2,277 crore in the March quarter, owing to one time charges related to settlement expenses and operations restructuring in some countries.

Novartis' cell therapy for follicular lymphoma in adults approved by FDA

FDA has granted Novartis accelerated approval for its CAR-T cell therapy Kymriah (tisagenlecleucel) to treat adults with relapsed or refractory (r/r) follicular lymphoma (FL) after two or more lines of systemic therapy.

FDA put halt on OTC version trial of anti-impotence drug Cialis

A trial to switch the prescription-only erectile dysfunction drug Cialis to an over-the-counter (OTC) treatment has been halted by the US Food and Drug Administration.

FDA approved Roche's Evrysdi for use in babies under the age of two months

FDA has approved a label extension for Evrysdi (risdiplam) to include babies under two months old with spinal muscular atrophy. The approval is based on preliminary efficacy and safety data from the RAINBOWFISH newborn study.

Strides Pharma received FDA approval for Ibuprofen oral suspension

Strides Pharma Science (Strides) announced that its step-down wholly owned subsidiary, Strides Pharma Global, Singapore, has received FDA approval for Ibuprofen oral suspension USP, 100 mg/5 mL.

Jubilant spend $193 million to double injectable capacity in US

The agreement, funded by the American Rescue Plan, will allow the company to double its injectable filling production capacity at its Spokane, Washington manufacturing facility for a total cost of $193 million, with completion scheduled for 2025.